Cargando…
Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas
There is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. There is currently no consensus on the optimum management of WHO grade II meningiomas. In this study, we identified the calcium binding extracellular matr...
Autores principales: | Sofela, Agbolahan A., Hilton, David A., Ammoun, Sylwia, Baiz, Daniele, Adams, Claire L., Ercolano, Emanuela, Jenkinson, Michael D., Kurian, Kathreena M., Teo, Mario, Whitfield, Peter C., Sahm, Felix, Hanemann, C. Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827565/ https://www.ncbi.nlm.nih.gov/pubmed/33429944 http://dx.doi.org/10.3390/ijms22020560 |
Ejemplares similares
-
GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma
por: Negroni, Caterina, et al.
Publicado: (2020) -
A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours
por: Adams, Claire L., et al.
Publicado: (2020) -
Constitutive activation of the EGFR–STAT1 axis increases proliferation of meningioma tumor cells
por: Ferluga, Sara, et al.
Publicado: (2020) -
The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma
por: Lyons Rimmer, Jade, et al.
Publicado: (2020) -
OPTC-1. Proteomic analysis of genetically stratified low-grade meningioma
por: Akther, Yeasmin, et al.
Publicado: (2021)